FDA advisers to assess drug for low sexual desire in womenBMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c2786 (Published 25 May 2010) Cite this as: BMJ 2010;340:c2786
- Ray Moynihan
- 1Byron Bay, Australia
Advisers to the US Food and Drug Administration will meet on 18 June to assess the drug flibanserin as a potential treatment for women said to have low sexual desire, or “hypoactive sexual desire disorder.”
Flibanserin was originally developed as an anti-depressant, but was not found to be effective and was never approved as one. Its German manufacturer Boehringer Ingelheim has recently released abstracts of unpublished randomised trials testing the drug’s potential sexual benefits in women.
According to the abstracts, the company’s trials of flibanserin in Europe failed to show any statistically significant benefit compared with placebo on the primary outcome measure: the number of “satisfying sexual events.” A satisfying sexual event can …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial